Please assess the completion status of the following clinical trial:

Trial Title: A Long Term Safety Study of Suvorexant in Participants With Primary Insomnia (MK-4305-009 AM3)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of primary insomnia~* Participant is able to read, understand, and complete questionnaires and diaries~* If female, participant and partner both agree to use acceptable contraception. If male partner does not use an effective form of contraception, female participant must use 2 acceptable forms of contraception~* If ≥65 years of age, score of ≥25 on the Mini Mental State Examination (MMSE)~Exclusion Criteria:~* If female, participant is pregnant~* Participant expects to donate eggs or sperm during the study~* Recent and/or active history of a confounding neurological disorder~* History of clinically unstable cardiovascular disorder within the last 6 months~* Lifetime history of bipolar disorder~* Psychiatric condition that requires treatment with a medication prohibited by the study, or any other psychiatric condition that would interfere with the participant's ability to participate in the study~* History of substance abuse/dependence~* History of cancer ≤5 years prior to study participation except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer~* Evidence of suicidality (based on a score of 2 on the Quick Inventory of Depressive Symptomatology Self-Report 16-Item (\[QIDS-SR16\] suicide item #12)~* Participant has travelled across \>3 time zones or \>3 hour time difference in the last 2 weeks~* History of permanent night shift work or rotating day/night shift work in the past 2 weeks~* Body Mass Index (BMI) \>40 kg/m\^2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Suvorexant (Type: EXPERIMENTAL): After a 1-week single-blind placebo run-in, participants received suvorexant (40 mg for participants aged 18 to \<65 years; and 30 mg for participants aged ≥65 years) daily before bedtime for 12 months during the Treatment Phase.
- Placebo (Type: PLACEBO_COMPARATOR): After a 1-week single-blind placebo run-in, participants received dose-matched placebo to suvorexant (administered according to age) daily before bedtime for 12 months during the Treatment Phase.

Based on this trial design, predict the completion outcome and termination type (if applicable).